Search
Now showing items 1-3 of 3
HIV/AIDS patients display lower relative bioavailability of Efavirenz than healthy subjects
(Adis Data Information BV., 2011)
Background: Pharmacokinetic studies of antiretroviral drugs are often conducted in adult healthy subjects, and the results are extrapolated to HIV/AIDS patients. HIV/AIDS, however, is known to cause morphological and ...
Non-linear mixed effects modeling of liver function biomarkers in TB-HIV patients co-treated with Rifampicin and Efavirenz based regimens
(2013-11)
Introduction
Survival has improved as a result of improved HIV therapy but liver disease remains a critical problem in HIV patients. HIV disease, ART and Tuberculosis treatments have all been documented to cause liver ...
Development and validation of an HPLC-UV method for the simultaneous determination of Efavirenz and Dolutegravir in human plasma
(Makerere University, 2022-12)
Background: Although HIV/AIDS possess a challenge, global efforts have been mounted to address the epidemic. These include the massive role out of anti-retroviral therapy (ART) globally. To date either efavirenz or ...